Realizing the full potential of ADCs by unlocking new classes of payloads

Firefly Bio

Firefly is excited to share that we've closed a $94M Series A to advance Degrader Antibody Conjugates (DACs) that combine the unique strengths of ADCs with selective protein degraders. We're funded by Versant Ventures, MPM BioImpact, Decheng Capital, and Eli Lilly & Co. 
https://lnkd.in/grEAF9U8

Co-Founder and CSO

John Flygare

Vice President Bioconjugate Chemistry

Sean Smith

Jerel Davis

Todd Foley

Bernhard Geierstanger

Co-Founder and Chief Technology Officer

Carolyn Bertozzi

Co-Founder

Scott Hirsch

Western US Companies With Fewer Than 100 Employees (Top 10K)

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Private California Companies (Top 10K)

California Companies With Fewer Than 1000 Employees (Top 10K)

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

MPM Capital

Versant Ventures

Series A - Firefly Bio

San Francisco

California

United States

North America

Versant-backed Firefly Bio wants to make the next generation of ADCs

Firefly Bio Debuts With $94 Million Series A Financing

Firefly Bio Unveils $94M to Illuminate the Startup's New Take on ADC Cancer Meds

Firefly Bio assembles with $94M and an ADC dream team to work on protein degraders

ADC-Focused Firefly Bio Emerges from Stealth with $94M Series A

Firefly Bio debuts with $94 million Series A financing

Firefly Bio's platform combines antibody drug conjugates with protein degraders to target cancer cells specifically, minimizing damage to healthy cells.

Firefly Bio's platform combines ADCs with selective protein degraders for targeted cancer therapy.

Developed to enable the creation of new ADC payloads, enhancing the range of therapeutic targets.

A proprietary technology that connects protein degraders with antibodies, reducing free payload in circulation and enhancing cell-specific targeting.

Includes medical, prescription, dental, and vision insurance, along with voluntary coverage options.

A technology that connects ADCs with protein degraders, reducing free payload in circulation and minimizing healthy cell uptake.

BeiGene is a global, commercial-stage biotechnology company focused on developing and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.

BeiGene

Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron Pharmaceuticals

Orum Therapeutics is a biopharmaceutical company focused on developing novel therapies for cancer treatment, including antibody-drug conjugates and other targeted therapies.

Orum Therapeutics

BioTheryx is a clinical-stage biotechnology company dedicated to developing targeted therapies for cancer, including antibody-drug conjugates and other precision medicines.

BioTheryx

Abcuro is a biotechnology company specializing in the development of antibody-based therapies, including antibody-drug conjugates, for the treatment of cancer and other serious diseases.

Abcuro

Cybrexa Therapeutics is a biotechnology company focused on developing next-generation antibody-drug conjugates and other targeted therapies for the treatment of cancer.

Cybrexa Therapeutics

Vividion Therapeutics is a biotechnology company that leverages cutting-edge drug discovery technologies to develop novel small molecule and antibody-based therapies for various diseases, including cancer.

Vividion Therapeutics

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases.

Genmab

Firefly Bio is a biotechnology company focused on developing new classes of payloads for Antibody-Drug Conjugates (ADCs) with the help of renowned researchers with decades of experience in ADC discovery and development.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 3, 2024 1:45 PM	3d30f596
public peers	general	May 3, 2024 1:45 PM	b3f719c9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 3, 2024 1:45 PM	4895853f
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	07924cb1
crunchbase profile	general	Nov 22, 2024 9:27 AM	8274d643
li profile	general	May 3, 2024 1:45 PM	44394f7f
translate crunchbase fundingrounds	general	Nov 22, 2024 1:58 PM	6308d60f
peers	general
news basic	general	May 3, 2024 1:45 PM	eb4cca1e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:FIREFLYBIOLOGICS

Firefly Bio